ELN:  Never say never, but I doubt it will get to 5-7.  Expect news soon on selling of speciality division-use funds to retire most of their heavy debt.  Down the road I expect them to get bought out?

 

Tysabri implicated in a couple of skin cancer safety cases recently-in the aged patient population, it does not seem to be about safety for Tysabri.  Actually looking at this drug to help with oncology indications.

 

Appears range-bound to me until next quarters eanings indicate damage/lack of damage to Tysabri sales.  Phase III Alzheimers proceeds.

 

Still nothing important from the FDA regarding Tysabri safety.  I hold my currently lightly profitable shares.

 

JMO

 

Kutz